Related Experiment Video
Updated: May 4, 2026
12:21
The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
Published on: November 26, 2015
18.9K
ALH-L1005 attenuates endotoxin induced inner ear damage
Chul Ho Jang1, Yong Beom Cho2, Cheol Hee Choi3
1Department of Otolaryngology, Chonnam National University Medical School, Gwangju, South Korea; Research Center for Resistant Cells, Chosun Medical School, Gwangju, South Korea.
International Journal of Pediatric Otorhinolaryngology
|January 15, 2014
Summary
This study investigated ALH-L1005 for protecting the cochlea from lipopolysaccharide (LPS)-induced damage. Results show ALH-L1005 effectively preserved cochlear hair cells and reduced damage, suggesting its therapeutic potential.
Area of Science:
- Oto-pharmacology
- Oto-immunology
- Cellular biology
Background:
- Lipopolysaccharide (LPS) can induce cochlear damage, leading to hearing loss.
- Matrix metalloproteinase-9 (MMP-9) activation is implicated in LPS-induced cochlear injury.
- Protecting the cochlea from inflammatory damage is a critical therapeutic challenge.
Purpose of the Study:
- To evaluate the efficacy of ALH-L1005 in preventing LPS-induced cochlear damage.
- To investigate the mechanism of ALH-L1005 action, focusing on MMP-9 inhibition.
Main Methods:
- In vitro assays assessed human umbilical vein endothelial cell (HUVEC) tube formation and MMP-9 inhibition.
- In vivo studies in guinea pigs involved intratympanic administration of LPS, oxytetracycline (positive control), or ALH-L1005.
- Auditory brainstem response (ABR), cochlear blood flow (CBF), blood-labyrinth barrier (BLB) permeability, and MMP-9 activity were measured.
Main Results:
- ALH-L1005 suppressed HUVEC tube formation and prominently inhibited MMP-9 activity.
- ALH-L1005 attenuated LPS-induced hearing threshold shifts and improved cochlear blood flow.
- Preservation of cochlear hair cells and significant reduction in BLB permeability were observed in the ALH-L1005 group.
Conclusions:
- ALH-L1005 demonstrates significant protective effects against LPS-induced cochlear lateral wall damage.
- The compound's mechanism involves MMP-9 inhibition and preservation of cochlear structures.
- ALH-L1005 shows promise as a therapeutic agent for preventing hearing loss due to cochlear injury.
